DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Biapenem
Biapenem
United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
Consideration of Antibacterial Medicines As Part Of
Cyslabdan, a New Potentiator of Imipenem Activity Against Methicillin-Resistant Staphylococcus Aureus, Produced by Streptomyces Sp
WO 2010/025328 Al
Chemical Properties Biological Description Solubility Information
Antibiotics Currently in Clinical Development
Interactions of Biapenem with Active-Site Serine and Metallo
202106Orig1s000
2000 Dialysis of Drugs
Recent Advances in the Development of Antibacterial Agents
WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
Author Section
In Vitro Activity of Biapenem and Comparators Against Multidrug
WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
APPLICATION of STRUCTURE ACTIVITY RELATIONSHIPS of the MYCOBACTERIUM TUBERCULOSIS BETA-LACTAMASE (Blac)
Antibiotics Currently in Clinical Development
6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
Top View
Vabomere, Through the Centralised Procedure Under Article 3 (2) (A) of Regulation (EC) No 726/2004
FDA-Approved Drug Library Mini (96-Well)
New Perspectives on Antibacterial Drug Research
NICE Guideline. Urinary Tract Infection (Lower): Antimicrobial Prescribing
Antibiotic Resistance Gene Resource and Assay List
New Treatment Options Against Gram-Negative Organisms Matteo Bassetti*, Francesca Ginocchio, Malgorzata Mikulska
Meropenem Monotherapy Is As Effective As and Safer Than Imipenem to Treat Brain Abscesses G
Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and Its Newer Rela Ves
Dosing of Amoxicillin / Clavulanic Acid in Geriatric Patients at the Emergency Department
(12) United States Patent (10) Patent No.: US 9,675,592 B2 Daum Et Al
Comparative in Vitro Activity of Piperacillinl Tazobactam Against Gram
AMR: Antimicrobial Resistance Data Analysis
Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
Elizabeth T. Escaño-Gallardo, MD, FPPS, FPIDSP 23Rd Annual Convention Pediatric Infectious Disease Society of the Philippines February 19, 2016 Objectives
NG198 Evidence Review G
Literature Search Strategy for Treatment of Stable
20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: an Update from the Infectious Diseases Society of America
K. Pneumoniae
K. Pneumoniae
NG198 Evidence Review F1
(12) Patent Application Publication (10) Pub. No.: US 2014/0186467 A1 DIGGS Et Al
PMDA Updates
Use of Carbapenems in Children Summary Carbapenems Are Betalactams with the Broadest Antibacterial Spectrum Currently Available
WO 2014/107535 Al 10 July 2014 (10.07.2014) W P O P C T
Transcriptome-Based Design of Antisense Inhibitors Potentiates Carbapenem Efficacy in CRE Escherichia Coli
Pharmaceutical Appendix to the Tariff Schedule 2
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Supramolecular Organization of Model Liquid Crystalline Ionomers
Pharmaceuticals Appendix
Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
Original Article Activities of Biapenem Against Mycobacterium Tuberculosis
Critically Important Antimicrobials for Human Medicine
Antibiotics in the Clinical Pipeline in 2013
Poster Session) Biapenem and Biapenem/RPX7009 MIC Quality Control Ranges Using CLSI Multi-Laboratory M23-A3 Study Design J.E
New Carbapenemase Inhibitors: Clearing the Way for the -Lactams
Medchemcomm Accepted Manuscript
Cat.No.T6411)
Biapenem PRODUCT DATA SHEET Issue Date 01/06/2020
(Carbavance) for Treatment Resistant Gram-Negative Bacterial Infections – First Line
Inductive QSAR Descriptors. Distinguishing Compounds with Antibacterial Activity by Artificial Neural Networks